Literature DB >> 20965585

Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study.

Alvaro Alonso1, Weihong Tang, Sunil K Agarwal, Elsayed Z Soliman, Alanna M Chamberlain, Aaron R Folsom.   

Abstract

BACKGROUND: Various hemostatic markers are associated with the risk of cardiovascular disease; however, limited information exists on their relationship with the occurrence and prognosis of atrial fibrillation (AF).
OBJECTIVES: To assess whether hemostatic markers are associated with the incidence and prognosis of AF.
METHODS: We studied 14,858 men and women in the Atherosclerosis Risk in Communities cohort, aged 45-64 and free of AF at baseline (1987-1989). Fibrinogen, von Willebrand factor (vWf), factor VII activity (VIIc), factor VIII activity (VIIIc), protein C, antithrombin III (ATIII), and activated partial thromboplastin time (aPTT) were measured in blood samples at baseline. AF and other cardiovascular outcomes through 2005 were determined following standardized protocols.
RESULTS: During a median follow-up of 16.8 years, 1209 cases of AF were identified. In multivariable Cox models, the hazard ratios (HR) and 95% confidence intervals (CI) of incident AF associated with a 1-standard deviation (SD) increase in each marker were 1.13 (1.07-1.20) for fibrinogen, 1.17 (1.11-1.23) for vWf, 1.17 (1.11-1.24) for factor VIIIc, 0.93 (0.88-1.00) for factor VIIc, 0.98 (0.92-1.04) for protein C, 1.00 (0.94-1.06) for aPTT and 1.00 (0.95-1.06) for ATIII. Greater factor VIIIc, fibrinogen and vWf were consistently associated with a higher risk of cardiovascular outcomes and mortality in those with and without incident AF, while greater protein C was associated with a lower risk of ischemic stroke.
CONCLUSION: Several hemostatic markers are associated with the incidence of AF independently of other cardiovascular risk factors. Their role in the risk stratification of AF patients should be further studied.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965585      PMCID: PMC3025309          DOI: 10.1016/j.ijcard.2010.09.051

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  38 in total

1.  Hemostatic state and atrial fibrillation (the Framingham Offspring Study).

Authors:  D Feng; R B D'Agostino; H Silbershatz; I Lipinska; J Massaro; D Levy; E J Benjamin; P A Wolf; G H Tofler
Journal:  Am J Cardiol       Date:  2001-01-15       Impact factor: 2.778

2.  Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Alanna M Chamberlain; Sunil K Agarwal; Marietta Ambrose; Aaron R Folsom; Elsayed Z Soliman; Alvaro Alonso
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

3.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

4.  Impact of atrial fibrillation on mortality, stroke, and medical costs.

Authors:  P A Wolf; J B Mitchell; C S Baker; W B Kannel; R B D'Agostino
Journal:  Arch Intern Med       Date:  1998-02-09

5.  Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry.

Authors:  Emelia J Benjamin; Kenneth M Rice; Dan E Arking; Arne Pfeufer; Charlotte van Noord; Albert V Smith; Renate B Schnabel; Joshua C Bis; Eric Boerwinkle; Moritz F Sinner; Abbas Dehghan; Steven A Lubitz; Ralph B D'Agostino; Thomas Lumley; Georg B Ehret; Jan Heeringa; Thor Aspelund; Christopher Newton-Cheh; Martin G Larson; Kristin D Marciante; Elsayed Z Soliman; Fernando Rivadeneira; Thomas J Wang; Gudny Eiríksdottir; Daniel Levy; Bruce M Psaty; Man Li; Alanna M Chamberlain; Albert Hofman; Ramachandran S Vasan; Tamara B Harris; Jerome I Rotter; W H Linda Kao; Sunil K Agarwal; Bruno H Ch Stricker; Ke Wang; Lenore J Launer; Nicholas L Smith; Aravinda Chakravarti; André G Uitterlinden; Philip A Wolf; Nona Sotoodehnia; Anna Köttgen; Cornelia M van Duijn; Thomas Meitinger; Martina Mueller; Siegfried Perz; Gerhard Steinbeck; H-Erich Wichmann; Kathryn L Lunetta; Susan R Heckbert; Vilmundur Gudnason; Alvaro Alonso; Stefan Kääb; Patrick T Ellinor; Jacqueline C M Witteman
Journal:  Nat Genet       Date:  2009-07-13       Impact factor: 38.330

6.  Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Folsom; T Ohira; K Yamagishi; M Cushman
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

7.  N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.

Authors:  Kristen K Patton; Patrick T Ellinor; Susan R Heckbert; Robert H Christenson; Christopher DeFilippi; John S Gottdiener; Richard A Kronmal
Journal:  Circulation       Date:  2009-10-19       Impact factor: 29.690

8.  Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study.

Authors:  L E Chambless; R McMahon; K Wu; A Folsom; A Finch; Y L Shen
Journal:  Ann Epidemiol       Date:  1992-09       Impact factor: 3.797

9.  Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.

Authors:  Renate B Schnabel; Martin G Larson; Jennifer F Yamamoto; Lisa M Sullivan; Michael J Pencina; James B Meigs; Geoffrey H Tofler; Jacob Selhub; Paul F Jacques; Philip A Wolf; Jared W Magnani; Patrick T Ellinor; Thomas J Wang; Daniel Levy; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

10.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom
Journal:  Am Heart J       Date:  2009-07       Impact factor: 4.749

View more
  26 in total

1.  Stroke or left atrial thrombus prediction using antithrombin III and mean platelet volume in patients with nonvalvular atrial fibrillation.

Authors:  Seo-Won Choi; Bo-Bae Kim; Dong-Hyun Choi; Geon Park; Byung Chul Shin; Heesang Song; DongHun Kim; Dong-Min Kim
Journal:  Clin Cardiol       Date:  2017-08-14       Impact factor: 2.882

2.  Atrial fibrillation, elevated troponin, ischemic stroke and adverse outcomes: understanding the connection.

Authors:  Rui Providência; Sérgio Barra; Luís Paiva
Journal:  Clin Res Cardiol       Date:  2013-06-24       Impact factor: 5.460

3.  Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Authors:  Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Myriam Fornage; Rulan S Parekh; Josef Coresh; Wen Hong Linda Kao
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

4.  Effect of ageing on the murine venous circulation.

Authors:  Bianca Hemmeryckx; Jan Emmerechts; Edwin G Bovill; Marc F Hoylaerts; H R Lijnen
Journal:  Histochem Cell Biol       Date:  2012-01-18       Impact factor: 4.304

Review 5.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

6.  sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Mahmoud Al Rifai; Andrea L C Schneider; Alvaro Alonso; Nisa Maruthur; Christina M Parrinello; Brad C Astor; Ron C Hoogeveen; Elsayed Z Soliman; Lin Y Chen; Christie M Ballantyne; Marc K Halushka; Elizabeth Selvin
Journal:  J Diabetes Complications       Date:  2014-11-25       Impact factor: 2.852

Review 7.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

8.  Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Jingjing Li; Sunil K Agarwal; Alvaro Alonso; Saul Blecker; Alanna M Chamberlain; Stephanie J London; Laura R Loehr; Ann Marie McNeill; Charles Poole; Elsayed Z Soliman; Gerardo Heiss
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

Review 9.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31

Review 10.  An update on the prognosis of patients with atrial fibrillation.

Authors:  David D McManus; Michiel Rienstra; Emelia J Benjamin
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.